In The News: School of Integrated Health Sciences
NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen's lead compound, NVG-291, in validated animal models of Alzheimer's disease.
The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice.
Many doctors appear uneasy about prescribing Aduhelm, as they continue to grapple with a long list of unknowns.
These women have proven time and again that limits can be pushed and determination is essential to a successful career.
Many doctors appear uneasy about prescribing Aduhelm, as they continue to grapple with a long list of unknowns.
A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for Alzheimer’s disease recently granted accelerated approval by the U.S. Food and Drug Administration (FDA).
Hallucinations and delusions are common in dementia and may be comorbid or part of the disease process (ie, dementia related psychosis [DRP]). DRP occurs in 30% of people with any type of dementia, 40% of those with Alzheimer disease and 70% of dementia with Lewy bodies.
Performing certain exercises can help you manage spasticity after a stroke.
Performing certain exercises can help you manage spasticity after a stroke.
The counterintuitive lesson everyday people can steal from Olympic athletes.
Not all physicians who treat Alzheimer's disease will prescribe the new Alzheimer's drug aducanumab (Aduhelm) -- major hospital systems like the Cleveland Clinic and Mount Sinai in New York City, for example, won't administer the controversial treatment -- but those who will offer the drug need more information about how to use it, a panel of neuroscientists said.
Appropriate use recommendations for the newly approved Alzheimer disease treatment, aducanumab (Aduhelm; Biogen, Cambridge, MA) have been published in The Journal of Prevention of Alzheimer’s Disease (JPAD).